Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials  by Nelson, Scott M. et al.
Comparison of antim€ullerian hormone
levels and antral follicle count as
predictor of ovarian response to
controlled ovarian stimulation in
good-prognosis patients at individual
fertility clinics in two multicenter trials
Scott M. Nelson, M.R.C.O.G., Ph.D.,a Bjarke M. Klein, Ph.D.,b and Joan-Carles Arce, M.D., Ph.D.c
a School ofMedicine, University of Glasgow, Glasgow, United Kingdom; and b Global Biometrics and c Reproductive Health,
Ferring Pharmaceuticals, Copenhagen, DenmarkObjective: To compare antim€ullerian hormone (AMH) and antral follicle count (AFC) as predictors of ovarian response to controlled
ovarian stimulation at individual fertility clinics.
Design: Retrospective analysis of individual study center data in two multicenter trials. Centers that provided >10 patients were
included in the analysis.
Setting: A total of 19 (n¼ 519 patients) and 18 study centers (n¼ 686 patients) participating in a long GnRH agonist trial (MERIT) and
a GnRH antagonist trial (MEGASET), respectively.
Patient(s): Infertile women of good prognosis.
Intervention(s): Long GnRH agonist or GnRH antagonist cycles.
Main Outcome Measure(s): Correlation between AMH and AFC, and oocyte yield by each study center for each trial.
Results(s): Antim€ullerian hormone was more strongly correlated with oocyte yield than AFC: r¼ 0.56 vs. r¼ 0.28 in the GnRH agonist
cohort, and r ¼ 0.55 vs. r ¼ 0.33 in the GnRH antagonist cohort. The correlation was numerically higher for AMH than for AFC at a
signiﬁcantly higher proportion of study centers: 17 (89%) and 15 (83%) centers in the long GnRH agonist and GnRH antagonist trial,
respectively. Assessment of the relative capacity of AMH and AFC for predicting oocyte yield demonstrated that AMH dominated the
model: AMH, R2¼ 0.29 and 0.23; AFC: R2¼ 0.07 and 0.07; AMHþ AFC: R2¼ 0.30 and 0.23 for long GnRH agonist and GnRH antag-
onist trials, respectively.
Conclusions(s): Antim€ullerian hormone was a stronger predictor of ovarian response to gonadotropin therapy than AFC at the studyUse your smartphonecenter level in both randomized trials utilizing GnRH agonist and GnRH antagonist protocols.
Antral follicle count provided no added predictive value beyond AMH. (Fertil Steril 2015;103:
923–30. 2015 by American Society for Reproductive Medicine.)
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VOL. 103 NO. 4 / APRIL 2015T he ovarian response resultingfrom controlled ovarian stimula-tion (COS) in IVF with standard
doses of gonadotropins is associated
with a large interindividual variability.
Individualization of the starting dose of
gonadotropin according to ovarian
reserve parameters has been proposed
as a means of improving safety and ef-
ﬁcacy of COS (1–3). To date, a number923
ORIGINAL ARTICLE: ASSISTED REPRODUCTIONof markers of ovarian response have been used and evaluated
(4), such as age, FSH, and inhibin B; however, antral follicle
count (AFC) and antim€ullerian hormone (AMH) are the two
biomarkers that have consistently provided the best
performance in terms of predicting ovarian response to
gonadotropins (5, 6).
Antral follicle count has been shown to possess similar
performance as AMH in predicting the number of oocytes
retrieved in the majority of single-center observational
cohort studies in IVF/intracytoplasmic sperm injection
(ICSI) patients treated with GnRH agonist protocols (7–11),
whereas a few studies have suggested either AFC (12, 13)
or AMH (14, 15) as being a better predictor. Two meta-
analyses of a number of these relatively small, single-
center studies indicated that AMH and AFC have similar
levels of accuracy and clinical value for the prediction of
poor (16) as well as excessive response (17). In marked
contrast to these reports, three recent large, prospective,
multicenter trials in IVF/ICSI patients of good prognosis
consistently concluded that AMH was a better predictor of
ovarian response than AFC in GnRH agonist (18) and antag-
onist (19, 20) cycles, regarding the number of oocytes
retrieved as well as categorization of low and high
responders. Furthermore, in models of ovarian response
AFC did not provide any additional predictive value
beyond that provided by AMH (18–20).
The overall superior performance of AMH over AFC in
these multicenter trials may have been attributed to consider-
able sonographer-dependent variability across centers.
Furthermore, such interoperator variability between different
IVF clinics may also explain the different performance of AFC
in single-center and multicenter studies. Therefore, it would
be important to explore whether the ﬁndings in multicenter
trials are determined by the integrated data evaluation rather
than by the actual performance at each study center, because
AMHwas analyzed centrally and AFC locally. This is essential
to clarify, given the perception that each fertility clinic be-
lieves that their ultrasound evaluation of AFC is robust, and
because AFC has been considered the gold standard
biomarker for the prediction of ovarian response.
The aim of the present study was to compare the values of
AMH and AFC for prediction of oocyte yield at a study center
level for fertility clinics participating in two large, multicenter
trials: one conducted with the long GnRH agonist protocol
(21) and the other with a GnRH antagonist protocol (22).
Consistent with previous systematic reviews and individual
patient data meta-analyses (4, 23, 24), other predictors of
ovarian response to gonadotropin stimulation, such as FSH,
were shown to be less predictive than AMH in both trials
(18, 19) and therefore not considered for this evaluation.MATERIALS AND METHODS
Study Population and Study Centers
This study is a retrospective analysis of data prospectively
collected in two randomized, controlled, multicenter trials
in IVF/ICSI patients of good prognosis undergoing COS
with highly puriﬁed hMG (Menopur; Ferring Pharmaceuti-
cals) or recombinant FSH (follitropin alfa [Gonal-F, Merck924Serono] or follitropin beta [Puregon, MSD]) after a long
GnRH agonist protocol (MERIT trial) (21) or a GnRH antago-
nist protocol (MEGASET trial) (22). The women included in
each trial had been infertile for at least 1 year and had a reg-
ular menstrual cycle, a transvaginal ultrasound documenting
presence and adequate visualization of both ovaries without
evidence of abnormality, and an early follicular-phase serum
level of FSH within normal limits (1–12 IU/L). Women with
polycystic ovary syndrome and/or a poor response in a previ-
ous COS cycle were excluded in both trials. In the GnRH
antagonist trial, women with an AFC <10 (diameter 2–
10 mm) at screening were excluded. At each study center,
the patients were randomized in a 1:1 ratio to treatment
with either highly puriﬁed hMG or rFSH.
The trials were conducted in accordance with the Decla-
ration of Helsinki, the International Conference on Harmoni-
zation Guidelines for Good Clinical Practice, and local
regulatory requirements, and were approved by the local reg-
ulatory authorities and the independent ethics committees
covering all participating study centers. Written informed
consent was provided by each of the subjects.Stimulation Regimens
In the long GnRH agonist trial, pituitary suppression was
initiated with 0.1 mg/d of triptorelin (Decapeptyl, Ferring
Pharmaceuticals) 5–7 days before the estimated start of
next menses and continued until the end of gonadotropin
administration. Gonadotropin treatment started when
down-regulation was conﬁrmed, and the dose was ﬁxed at
225 IU/d for the ﬁrst 5 days of COS, followed by individual
dose adjustments according to the patient's follicular
response. In the GnRH antagonist trial, treatment with a daily
dose of 150 IU of gonadotropin started on day 2–3 of themen-
strual cycle and was ﬁxed for the ﬁrst 5 days of COS, followed
by individual dose adjustments according to the patient's
follicular response. Treatment with 0.25 mg/d of ganirelix
(Orgalutran, MSD) was initiated on stimulation day 6 and
continued throughout the gonadotropin treatment period. In
both trials, the criteria for giving hCG (Ovitrelle, Merck
Serono) was development of at least three follicles with a
diameterR17 mm. Oocyte retrieval took place 36  2 hours
later, followed by IVF or ICSI and embryo/blastocyst transfer.
Detailed descriptions of ovarian stimulation regimens, cohort
assessments, and procedures in the long GnRH agonist and
antagonist trials are provided in Nyboe Andersen et al.
(2006) (21) and Devroey et al. (2012) (22), respectively.Endocrine Assays and Antral Follicle Count
In both trials, circulating concentrations of AMH were
analyzed in serum samples collected on stimulation day 1
before the start of stimulation by a central laboratory (Hor-
mone Laboratory, Universitair Ziekenhuis, Brussels, Ger-
many for the agonist trial and Laboratory for Clinical
Research, Kiel, Germany for the antagonist trial). Serum
samples were immediately frozen to 18C for the ﬁrst
2 weeks until transport to a central facility, followed by
storage at 70C. Antim€ullerian hormone was analyzed byVOL. 103 NO. 4 / APRIL 2015
TABLE 1
Demographics, baseline characteristics and outcome.
Variable
Long GnRH
agonist trial
(19 study
centers,
519 patients)
GnRH
antagonist
trial (18
study centers,
686 patients)
P
value
Demographics
Age (y) 30.9  3.2 30.5  2.7 .059
Body weight (kg) 61.9  8.3 60.2  6.9 < .001
BMI (kg/m2) 22.2  2.6 22.0  2.0 .103
Cycle length (d) 28.4  1.7 28.6  1.9 .022
Fertility and Sterility®an enzyme-linked immunosorbent assay (long GnRH
agonist trial: Immunotech Beckman Coulter AMH ELISA
[A11893]; GnRH antagonist trial: Beckman Coulter Gen 2
AMH ELISA [A79765]; 1 ng/mL ¼ 7.143 pmol/L) without
predilution. The AMH assays had a sensitivity of 0.35 and
0.08 ng/mL and total imprecision (percent coefﬁcient of
variation) of <9.5 and <7.7 in Immunotech Beckman
Coulter and Beckman Coulter Gen 2, respectively. Antral fol-
licle count was the total number of follicles with a diameter
between 2 and 10 mm in both ovaries on stimulation day 1
before the start of stimulation, as measured by transvaginal
ultrasound by local sonographers at each study center.Duration of
infertility (y)
4.0  2.3 3.2  1.8 < .001
First treatment cycle 365 (70) 513 (75) .085
Stimulation day 1
AMH (pmol/L) 29.8  16.5 27.3  19.1 .013
AFC (n) 11.3  6.4 15.7  5.6 < .001
FSH (IU/L) 4.0  2.1 7.4  2.1 < .001
LH (IU/L) 2.3  1.4 6.2  2.2 < .001
E2 (pmol/L) 42.3  23.5 178  94 < .001
P (nmol/L) 1.2  0.6 2.3  2.1 < .001
Outcome
Oocytes retrieved (n) 11.0  5.7 9.9  5.6 < .001
Ongoing
pregnancy rate
141 (27) 199 (29) .482
Live birth rate 140 (27) 193 (28) .656
Note: Values are mean  SD or n (%).
Nelson. AMH vs. AFC as predictor of oocyte yield. Fertil Steril 2015.Statistical Analysis
Selected baseline characteristics and outcome variables are
presented using mean and SD, or as frequencies and percent-
ages. The populations were compared using t tests and c2
tests. The Spearman rank correlation coefﬁcients between
oocytes retrieved and the potential predictor variables
‘‘AMH’’ and ‘‘AFC’’ were calculated within each individual
study center, and within each study cohort. The capability
of AMH and AFC to predict the number of oocytes retrieved
was evaluated using a stepwise forward selection procedure
within an analysis of covariance model framework. The pro-
cedure sequentially selected the predictor variables according
to the increase in the coefﬁcient of determination (R2). The
relative importance of AMH and AFC with respect to predict-
ing the number of oocytes retrieved was further illustrated us-
ing partial residual plots. Besides the predictor variables AMH
and AFC, the variable ‘‘Study Center’’ was also included as a
factor accounting for differences in oocyte pickup proce-
dures/effectiveness between the clinics. Study centers
included in the primary analysis were those providing more
than 10 patients who underwent oocyte retrieval in either trial
and had assessments of both AMH and AFC before start of
stimulation. This cut-off was a compromise between not
including centers with too few patients, which could poten-
tially give misleading results in the evaluation of individual
study centers, and not excluding too many study centers/pa-
tients. Two additional sensitivity analyses were performed for
the forward selection procedure: inclusion of all contributing
centers, and restriction to those centers contributing R20
patients. All statistical analyses were performed in SAS
version 9.3 (SAS Institute).
RESULTS
In total, the long GnRH agonist trial and the GnRH antagonist
trial comprised 37 and 25 study centers, respectively. Of these,
19 study centers in the long GnRH agonist trial and 18 centers
in the GnRH antagonist trial contributedmore than 10 patients
who underwent oocyte retrieval and had baseline measure-
ments ofAMHandAFC (Supplemental Fig. 1, available online).
Demographics, baseline characteristics, andmain outcome pa-
rameters of the two study cohorts (longGnRHagonist trial: n¼
519 patients; GnRH antagonist trial: 686 patients) are pre-
sented in Table 1. There were no clinically relevant differences
between the two cohorts regarding the demographics and
serum levels of AMH on stimulation day 1. At start of COS,VOL. 103 NO. 4 / APRIL 2015the down-regulated patients in the long GnRH agonist cohort
had lower AFC, FSH, LH, E2, and P than the patients in the
GnRH antagonist cohort. Regarding stimulation and treatment
outcome, the mean number of oocytes retrieved was higher in
patients treatedwith the longGnRHagonist protocol compared
with that in the GnRH antagonist protocol, but the observed
live birth rates of the fresh stimulation cycle were similar (i.e.,
27% and 28% in the long GnRH agonist and GnRH antagonist
cohorts, respectively).
AMH and AFC as Biomarkers of Ovarian Response
at Individual IVF Clinics
Overall, AMH was a markedly better predictor of the number
of oocytes retrieved than AFC in both study cohorts. The
Spearman correlation coefﬁcient was 0.56 (95% conﬁdence
interval [CI] 0.50–0.62) for AMH in the long GnRH agonist
trial and 0.55 (95% CI 0.50–0.60) in the GnRH antagonist trial,
as compared with 0.28 (95% CI 0.20–0.36) and 0.33 (95% CI
0.26–0.39), respectively, for AFC (Fig. 1). Furthermore, in pa-
tients participating in the GnRH antagonist trial where ICSI
was used as a method of insemination, the correlation be-
tween AMH and number of metaphase II oocytes was higher
than that between AFC and metaphase II oocytes (0.45 [95%
CI 0.39–0.51] vs. 0.30 [95% CI 0.23–0.37]). In addition, sensi-
tivity analyses showed that AMH had higher correlation with
oocyte yield than AFC, irrespective of whether women
achieved a pregnancy (data not shown).
At individual IVF clinics, the correlation coefﬁcient with
oocyte yield for AMH was numerically higher than that for
AFC in 17 (89%) of the 19 study centers in the long GnRH
agonist trial and in 15 (83%) of the 18 study centers in the
GnRH antagonist trial (Fig. 1). In both trials, the observed925
FIGURE 1
Correlations between AMH and AFC, respectively, and number of oocytes retrieved in patients participating in a long GnRH agonist trial (A) and a
GnRH antagonist trial (B) at individual IVF clinics. The dotted lines show the overall mean correlation coefﬁcients of AMH and AFC for the study
cohorts. Antim€ullerian hormone was a stronger predictor of oocyte yield (i.e., a difference in correlation coefﬁcient of >0.10) in study center
nos. 1, 3, 4, 5, 6, 9, 11, 12, 14, 16, 17, 18, and 19 in the long GnRH agonist trial, and in study center nos. 1, 2, 3, 4, 9, 11, 12, 13, 14, 15, 17,
and 18 in the GnRH antagonist trial. Only study center no. 15 in the long GnRH agonist trial exhibited a stronger association with AFC.
Nelson. AMH vs. AFC as predictor of oocyte yield. Fertil Steril 2015.
ORIGINAL ARTICLE: ASSISTED REPRODUCTIONoutcome (i.e. that AMH was better than AFC at most centers)
was signiﬁcantly different compared with the outcome ex-
pected if AMHandAFCwere equally good predictors (binomial
test: P< .001 and P¼ .007 in the long GnRH agonist and GnRH
antagonist trials, respectively). When considering a difference
in correlation coefﬁcient of%0.10 (the smallest width of the92695% conﬁdence interval in the analysis) between AMH and
AFC as an indicator of similar performance, AMHwas a stron-
ger predictor of oocyte yield in 13 study centers (68%) in the
long GnRH agonist trial and 12 study centers (67%) in the
GnRH antagonist trial. Only one center (5%) exhibited stronger
association with AFC in the long GnRH agonist trial.VOL. 103 NO. 4 / APRIL 2015
Fertility and Sterility®Stepwise Regression Model
The stepwise forward procedure for prediction of number of
oocytes retrieved provided similar ﬁndings on the contribu-
tion of the selected predictors for the two cohorts (Table 2).
Antim€ullerian hormone was identiﬁed as the variable with
the highest coefﬁcient of determination: R2 ¼ 0.29 and 0.23
for the long GnRH agonist trial and the GnRH antagonist trial,
respectively. The R2 for AFC was only 0.07 in both trials, and
inclusion of AFC in the models had no signiﬁcant improve-
ment on the prediction of oocyte yield. In the long GnRH
agonist trial, the R2 increased slightly, from 0.29 (AMH) to
0.30 (AMH þ AFC), whereas there was no change in the
GnRH antagonist trial (i.e., R2 ¼ 0.23 both for AMH and
AMH þ AFC). Similar to the results obtained in the two study
cohorts, sensitivity analyses showed comparable outcomes
when restricting the analysis to centers with R20 patients
(long GnRH agonist trial [n ¼ 11 centers]: R2 ¼ 0.28 and
0.07 for AMH and AFC, respectively; GnRH antagonist trial
[n ¼ 11 centers]: R2 ¼ 0.23 and 0.06 for AMH and AFC,
respectively), as well as when including all study centers
with AMH and AFC data (long GnRH agonist trial: R2 ¼
0.28 and 0.07 for AMH and AFC, respectively; GnRH antago-
nist trial: R2¼ 0.24 and 0.08 for AMH and AFC, respectively).
The relative importance of AMH and AFC with respect to
predicting number of oocytes retrieved is further illustrated in
Figure 2. The plots of partial residuals obtained after adjusting
the number of oocytes retrieved for AFC and Study Center
against AMH indicated a strong linear relationship (Fig. 2A
and B). Reversing the roles of AMH and AFC indicated that
only a small improvement is gained when adding AFC if
AMH is already included in the model (Fig. 2C and D).
In a hypothetical prediction model that would consider
study site contribution for explaining oocytes retrieved, in-
clusion of the variable Study Center would lead to the second
largest improvement of the coefﬁcient of determination be-
sides AMH (i.e., from 0.29 to 0.40 and from 0.23 to 0.33 for
the long GnRH agonist trial and the GnRH antagonist trial,
respectively) (Table 2). Also in this case, inclusion of AFC
did not improve the prediction of oocyte yield, either in the
long GnRH agonist or the GnRH antagonist cohort.DISCUSSION
At present, several single-center studies have suggested that
AMH and AFC have the same level of accuracy and clinical
value for ovarian response prediction in women undergoingTABLE 2
Stepwise analysis of covariance models.
Model
R2, long GnRH
agonist trial
R2, GnRH
antagonist trial
AMH 0.29 0.23
AFC 0.07 0.07
Study Center 0.11 0.07
AMH þ AFC 0.30 0.23
AMH þ Study Center 0.40 0.33
AMH þ Study Center þ AFC 0.41 0.34
Nelson. AMH vs. AFC as predictor of oocyte yield. Fertil Steril 2015.
VOL. 103 NO. 4 / APRIL 2015IVF treatment (5, 16, 17). The assumption that these two
biomarkers of ovarian reserve possess similar performance
has, however, been questioned by three recent large,
multicenter trials (18–20). In each of these trials, analysis of
the integrated data obtained from the participating study
centers showed that AFC by itself was a poorer predictor of
the ovarian response to COS than AMH, and furthermore,
that AFC provided no added predictive value beyond AMH.
The ﬁnding that AMHwas a more robust biomarker of the
ovarian response to gonadotropins across multicenter trials
than AFC was also conﬁrmed in the present study, which
evaluated individual study center data from two of these tri-
als, one using a long GnRH agonist protocol (21) and the other
a GnRH antagonist protocol (22). The correlation coefﬁcient
for AMH and number of oocytes retrieved was numerically
higher in most centers (approximately 85%), regardless of
the protocol and the different gonadotropin doses used,
because stimulation was started with a dose of 225 IU in the
long GnRH agonist protocol and 150 IU in the GnRH antago-
nist protocol. The type of protocol or the different starting
doses between trials may have inﬂuenced the oocyte yield,
because the mean number of oocytes retrieved was slightly
lower in the GnRH antagonist trial than in the long GnRH
agonist trial. Nevertheless, because the treatment effect was
constant for both AMH and AFC, it would not be expected
to alter the strength of association for the two biomarkers.
It should be noted that AFC was measured on stimulation
day 1 in both trials. However, the timing of ultrasound assess-
ment in relation to the pituitary desensitization in the long
agonist protocol is not considered to have signiﬁcantly
changed the AFC, because several previous studies have
demonstrated that the AFC is unaffected by down-
regulation (25–28). Furthermore, AFC has been shown to
possess similar value for prediction of ovarian response
irrespective of whether the assessment is performed before
or after pituitary down-regulation (26).
In comparison to AFC, the correlation coefﬁcient for
AMH and number of oocytes retrieved was remarkably con-
stant across centers. The observed variability of the correla-
tion coefﬁcients for AFC suggests not only a marked
difference in the performance of the ultrasound measure-
ments by the operators at the different clinics, it also indicates
a potential variability in AFC within clinics, because two-
thirds of the study centers in both trials had considerably
lower correlation between their AFC measurements and the
ovarian response compared with the serum assay of AMH.
Furthermore, inclusion of AFC in stepwise logistic regression
models did not improve the prediction of oocyte yield, consis-
tent with previous analyses using integrated data from all
participating centers (18–20). The somewhat lower apparent
variability of AFC values in the GnRH antagonist trial
compared with the long GnRH agonist trial may be
explained by the time interval between the two trials (2009/
2010 and 2004, respectively), because ultrasound
technology has improved during these years (29). However,
it should be noted that the value of AFC as a predictor of
oocyte yield was not improved in the GnRH antagonist trial.
Despite the timing of AFC being standardized for both
multicenter trials, biological and technical explanations927
FIGURE 2
Panels illustrating the capability of AMH and AFC to predict the number of oocytes retrieved for the long GnRH agonist trial (left) and the GnRH
antagonist trial (right). The upper panels (A, B) show the partial residuals from the model including study cohort, AFC, and Study Center plotted
against AMH. The lower panels (C, D) show the partial residuals from the model including study cohort, AMH, and Study Center plotted against
AFC.
Nelson. AMH vs. AFC as predictor of oocyte yield. Fertil Steril 2015.
ORIGINAL ARTICLE: ASSISTED REPRODUCTIONmay have contributed to its observed lower inter- and intra-
clinic prediction performance (30). Ultrasound measurement
of the functional ovarian reserve may overestimate the
number of follicles that will be sensitive to gonadotropin
stimulation because of possible inclusion of atretic follicles
in the total count (31). In clinical practice, the measurement
of AFC is known to show substantial intra- and interoperator
variability regarding scanning techniques and methodology
for counting and measuring follicles (25, 32), and
larger clinics may work in teams with different
sonographers. Furthermore, technical aspects of ultrasound
equipment (e.g., resolution, depth) and different devices
(two-dimensional vs. three-dimensional) may affect the
performance of AFC measurements (33). Overall, the lack of
reproducibility would emphasize the necessity for individual
clinics to better standardize the assessment of AFC (34) but
also to develop their own thresholds for prediction of ovarian
response categories for AFC, rather than relying on existing
literature.928Antim€ullerian hormone was analyzed in a central labora-
tory, which may have reduced variation and improved overall
performance, but this reﬂects current clinical practice for the
majority of clinics. It should be noted that different AMH as-
says were used in the two multicenter trials (long GnRH
agonist trial: Immunotech Beckman Coulter AMH ELISA;
GnRH antagonist trial: Beckman Coulter Gen 2 AMH ELISA),
and that both assays, like the AFC measurements, were asso-
ciated with intra- and interindividual imprecision. Moreover,
although the blood samples were managed and analyzed ac-
cording to the manufacturers' instructions at the time of the
trials, there was a potential risk of complement interference
with the Beckman Coulter Gen 2 AMH assay (35). Neverthe-
less, despite these potential sources of errors regarding the as-
says, AMH performedmarkedly better than AFC in both trials.
Antim€ullerian hormone performance may also improve
further with the introduction of assays in an automated plat-
form with high reproducibility and not subject to complement
interference (36).VOL. 103 NO. 4 / APRIL 2015
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will also be affected by the oocyte retrieval procedure/oper-
ator at the IVF clinic, as indicated by the present prediction
model. However, because AMH and AFC are highly linked
to each other, it is anticipated that this center-speciﬁc effect,
in other words, the ability of the center to accurately retrieve
the oocytes available after stimulation, would affect equally
the relationship between oocytes retrieved and AFC, as well
as between oocytes retrieved and AMH levels. Nevertheless,
the prediction model that accounted for differences in oocyte
retrieval procedures between the study centers showed that
AMH was the variable with the highest predictive value and
that no further enhancement of the prediction of ovarian
response could be achieved by the inclusion of AFC compared
with AMH alone.
As mentioned above, the usefulness of AFC as a predictor
of ovarian response has primarily been demonstrated in
single-center, observational cohorts. Although the aim of
an observational study is to examine the association of a pre-
dictor/exposure (AFC or AMH) with an outcome (oocyte
yield), a major limitation is the potential for confounding
(37, 38). Confounding may be reduced in observational
studies by prevention in the design phase by restriction or
matching; and adjustment in the statistical analysis by
techniques such as stratiﬁcation or multivariable analyses.
These methods, however, require that the confounding
variables are known and measured. Notably, few of the
single-center studies that compared AMH and AFC as predic-
tive biomarkers have undertaken this level of detailed ana-
lyses. It is therefore possible that in the observational cohort
studies reported to date, confounding could have potentially
strengthened or weakened the predictive effect of AFC and
AMH against oocyte yield (39). Observational cohort studies
may also be subject to selection bias, particularly because
the value of the test may have inﬂuenced in advance the allo-
cation of treatment and thus the outcome of interest (ovarian
response). This was not the case in the present setting, in
which all subjects were managed in a harmonized and similar
manner independently of the variables of interest, including
randomly assigned choice of gonadotropin preparation,
similar schedule for monitoring of the follicular development,
and a common triggering criterion for follicular maturation
and same hCG dose. Although the generalizability of random-
ized controlled trials (RCTs) can be limited owing to the
stricter inclusion criteria and rigid protocols to generate
more homogenous study cohorts, RCTs are speciﬁcally de-
signed to overcome the issues of differential confounding
and selection bias between the treatment groups, making
them strong candidates to examine the strength of association
between exposures and outcomes of interest. Furthermore, in
prediction modeling of ovarian response to COS with gonad-
otropins, the treatment effect may either be dependent on pre-
dictive factors or be constant. Although we are accustomed in
reproductive medicine for the treatment effect to be modiﬁed
by predictive factors (e.g., age), ideally there should be a con-
stant treatment effect. This implies that we would require ex-
amination of how these predictors have performed in RCTs to
truly assess their performance characteristics, where the
treatment has been randomly allocated.VOL. 103 NO. 4 / APRIL 2015Although the present study has a number of strengths,
including its size, the use of two prospective, multicenter
RCTs utilizing two different stimulation strategies, inclusion
of a large number of clinics with experience in clinical
research, and robust statistical analyses, we do acknowledge
several limitations. Only patients with an anticipated good
prognosis to gonadotropin stimulation, based on serum FSH
1–12 IU/L (and AFCR10 in the GnRH antagonist trial), were
included. Because expected poor responders were excluded,
this selection may have attenuated the overall strength of the
correlations given that only women within the normal range
of AFC values were examined, but this limitation would also
apply toAMH. The highermeanAFCvalue in theGnRHantag-
onist cohort comparedwith the longGnRHagonist cohortmay
be explained bymore reﬁnedultrasound equipment during the
recent decade, and that AFC R10 was one of the inclusion
criteria in this trial. Differentmachineswere used formeasure-
ment of AFC at each of the centers, but this reﬂects current
clinical practice, and center-speciﬁc differences were
accounted for in the multivariate analysis, with no additional
contribution from AFC observed. No data on individual
sonographers were available, and it was therefore not possible
to examine their contribution at a study center level. Finally,
two sensitivity analyses, one after a further restriction to cen-
ters withR20 patients and the other after expanding the anal-
ysis cohorts to also include the centers contributing with%10
patients, resulted in an identical conclusion that AMH is a
stronger predictor of oocyte yield than AFC. Although AMH
wasapoorpredictor of embryo/blastocyst quality andongoing
pregnancy in the fresh cycle in bothmulticenter trials (18, 19),
a positive association betweenAMHand cumulative live-birth
rates in fresh and cryopreserved cycles has previously been re-
ported in the GnRH antagonist trial. This is consistent with
recent analyses of the strength of the association of AMH
and live birth (40), and potentially reﬂects the availability of
more oocytes and blastocysts for transfer in patients with
higher AMH rather than a direct association between AMH
and blastocyst quality (19).
In conclusion, when evaluating the data from two large,
multicenter trials at the study center level, the analysis
showed that AMH was a stronger predictor of ovarian
response to gonadotropin therapy than AFCwithin the major-
ity of the individual IVF clinics in both long GnRH agonist
and GnRH antagonist protocols. Further, inclusion of AFC
in the prediction models provided no added predictive value
beyond AMH. These ﬁndings argue against the general
assumption that the overall superior performance of AMH
over AFC in multicenter trials is only attributed to marked
sonographer-dependent variability across centers.
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